InsiderSignal.AI

InsiderSignal.ai

ESPR - Esperion Therapeutics, Inc.

Insider Sale by Koenig Sheldon L. (Pres, CEO)

1 Month
After Trade
Before Trade

Loading data...

Trade Summary

6 days ago, Koenig Sheldon L., serving as Pres, CEO at Esperion Therapeutics, Inc. (ESPR), sold 25,578 shares at $2.72 per share, for a total transaction value of $69,547.00. Following this transaction, Koenig Sheldon L. now holds 2,172,699 shares of ESPR.

This sale represents a 1.00% decrease in Koenig Sheldon L.'s stake in the company. This is considered a medium-conviction trade.

The trade was executed on Tuesday, March 17, 2026 and publicly disclosed via SEC Form 4 filing on Wednesday, March 18, 2026, 1 day after the trade was made.

Esperion Therapeutics, Inc. operates in the HEALTHCARE sector, specifically within the DRUG MANUFACTURERS - SPECIALTY & GENERIC industry. Insider selling activity in this sector can provide valuable signals about industry trends and company-specific developments.

Koenig Sheldon L.

Pres, CEO

Sheldon L. Koenig is the President, Chief Executive Officer, and Director of Esperion Therapeutics, Inc. (NASDAQ: ESPR), roles he has held since May 2021, after joining as Chief Operating Officer in December 2020.[[1]](https://fintool.com/app/research/companies/ESPR/people/sheldon-koenig)[[2]](https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-espr/esperion-therapeutics/management) At age 59, he holds an MBA from Monmouth University and a BAS from Drexel University.[[1]](https://fintool.com/app/research/companies/ESPR/people/sheldon-koenig)[[2]](https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-espr/esperion-therapeutics/management) Koenig brings over 35 years of pharmaceutical industry experience, including prior positions as EVP and Chief Commercial Officer at Portola Pharmaceuticals (2019–2020), SVP and Head of Cardiovascular Franchise at Sanofi (2016–2018), and VP and Global Brand Leader in Merck's Cardiovascular division, where he led the launch of ezetimibe.[[1]](https://fintool.com/app/research/companies/ESPR/people/sheldon-koenig)[[3]](https://clarivate.com/podcasts/bioworld-insider/esperion-therapeutics-ceo-sheldon-koenig/) Under his leadership at Esperion, the company has focused on commercializing bempedoic acid products (Nexletol and Nexlizet) for LDL cholesterol reduction and cardiovascular risk prevention, strengthened its capital structure, and advanced a pipeline targeting cardiometabolic diseases like primary sclerosing cholangitis.[[3]](https://clarivate.com/podcasts/bioworld-insider/esperion-therapeutics-ceo-sheldon-koenig/) His 2024 total compensation was approximately $3.18 million, with 0.19% ownership in the company.[[2]](https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-espr/esperion-therapeutics/management)

View full insider profile →

Trade Price

$2.72

Quantity

25,578

Total Value

$69,547.00

Shares Owned

2,172,699

Trade Date

Tuesday, March 17, 2026

6 days ago

SEC Filing Date

Wednesday, March 18, 2026

Filed 1 day after trade

HEALTHCAREDRUG MANUFACTURERS - SPECIALTY & GENERIC

About Esperion Therapeutics, Inc.

Company Overview

No company information available
View news mentioning ESPR

💬 Want Deeper Insight?

Use our AI assistant to ask questions about this trade, the insider, or the company.

Chat with AI

Share this trade

https://insidersignal.ai/trade/4896058

🚀 Track Insider Trades in Real-Time

Create a free account to access our full database of insider trades, AI-powered analysis, price alerts, and discover what corporate executives are buying and selling.

Create Free AccountLearn More

✓ Free forever plan available  •  ✓ No credit card required  •  ✓ Cancel anytime